283 related articles for article (PubMed ID: 24019259)
1. Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection.
Milla CE; Chmiel JF; Accurso FJ; VanDevanter DR; Konstan MW; Yarranton G; Geller DE;
Pediatr Pulmonol; 2014 Jul; 49(7):650-8. PubMed ID: 24019259
[TBL] [Abstract][Full Text] [Related]
2. Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trial.
François B; Luyt CE; Dugard A; Wolff M; Diehl JL; Jaber S; Forel JM; Garot D; Kipnis E; Mebazaa A; Misset B; Andremont A; Ploy MC; Jacobs A; Yarranton G; Pearce T; Fagon JY; Chastre J
Crit Care Med; 2012 Aug; 40(8):2320-6. PubMed ID: 22622405
[TBL] [Abstract][Full Text] [Related]
3. Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa.
Sawa T; Ito E; Nguyen VH; Haight M
Hum Vaccin Immunother; 2014; 10(10):2843-52. PubMed ID: 25483637
[TBL] [Abstract][Full Text] [Related]
4. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
McCoy KS; Quittner AL; Oermann CM; Gibson RL; Retsch-Bogart GZ; Montgomery AB
Am J Respir Crit Care Med; 2008 Nov; 178(9):921-8. PubMed ID: 18658109
[TBL] [Abstract][Full Text] [Related]
5. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
[TBL] [Abstract][Full Text] [Related]
6. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model.
Imamura Y; Yanagihara K; Fukuda Y; Kaneko Y; Seki M; Izumikawa K; Miyazaki Y; Hirakata Y; Sawa T; Wiener-Kronish JP; Kohno S
Eur Respir J; 2007 May; 29(5):965-8. PubMed ID: 17301098
[TBL] [Abstract][Full Text] [Related]
7. Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa.
Geller DE; Flume PA; Staab D; Fischer R; Loutit JS; Conrad DJ;
Am J Respir Crit Care Med; 2011 Jun; 183(11):1510-6. PubMed ID: 21471106
[TBL] [Abstract][Full Text] [Related]
8. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
Gibson RL; Emerson J; McNamara S; Burns JL; Rosenfeld M; Yunker A; Hamblett N; Accurso F; Dovey M; Hiatt P; Konstan MW; Moss R; Retsch-Bogart G; Wagener J; Waltz D; Wilmott R; Zeitlin PL; Ramsey B;
Am J Respir Crit Care Med; 2003 Mar; 167(6):841-9. PubMed ID: 12480612
[TBL] [Abstract][Full Text] [Related]
9. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
Tiddens HA; De Boeck K; Clancy JP; Fayon M; H G M A; Bresnik M; Derchak A; Lewis SA; Oermann CM;
J Cyst Fibros; 2015 Jan; 14(1):111-9. PubMed ID: 25091537
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
Retsch-Bogart GZ; Quittner AL; Gibson RL; Oermann CM; McCoy KS; Montgomery AB; Cooper PJ
Chest; 2009 May; 135(5):1223-1232. PubMed ID: 19420195
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind, placebo-controlled, dose-escalating study of aerosolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease.
Moss RB; Mayer-Hamblett N; Wagener J; Daines C; Hale K; Ahrens R; Gibson RL; Anderson P; Retsch-Bogart G; Nasr SZ; Noth I; Waltz D; Zeitlin P; Ramsey B; Starko K
Pediatr Pulmonol; 2005 Mar; 39(3):209-18. PubMed ID: 15573395
[TBL] [Abstract][Full Text] [Related]
12. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
13. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection.
Clancy JP; Dupont L; Konstan MW; Billings J; Fustik S; Goss CH; Lymp J; Minic P; Quittner AL; Rubenstein RC; Young KR; Saiman L; Burns JL; Govan JR; Ramsey B; Gupta R;
Thorax; 2013 Sep; 68(9):818-25. PubMed ID: 23749840
[TBL] [Abstract][Full Text] [Related]
14. Controlled trial of inhaled budesonide in patients with cystic fibrosis and chronic bronchopulmonary Psuedomonas aeruginosa infection.
Bisgaard H; Pedersen SS; Nielsen KG; Skov M; Laursen EM; Kronborg G; Reimert CM; Høiby N; Koch C
Am J Respir Crit Care Med; 1997 Oct; 156(4 Pt 1):1190-6. PubMed ID: 9351621
[TBL] [Abstract][Full Text] [Related]
15. The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.
Emiralioglu N; Yalcin E; Meral A; Sener B; Dogru D; Ozcelik U; Kiper N
J Clin Pharm Ther; 2016 Aug; 41(4):419-23. PubMed ID: 27311742
[TBL] [Abstract][Full Text] [Related]
16. Levofloxacin inhalation solution for the treatment of chronic Pseudomonas aeruginosa infection among patients with cystic fibrosis.
Stockmann C; Hillyard B; Ampofo K; Spigarelli MG; Sherwin CM
Expert Rev Respir Med; 2015 Feb; 9(1):13-22. PubMed ID: 25417708
[TBL] [Abstract][Full Text] [Related]
17. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection.
Trapnell BC; McColley SA; Kissner DG; Rolfe MW; Rosen JM; McKevitt M; Moorehead L; Montgomery AB; Geller DE;
Am J Respir Crit Care Med; 2012 Jan; 185(2):171-8. PubMed ID: 22095545
[TBL] [Abstract][Full Text] [Related]
18. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection.
Moskowitz SM; Emerson JC; McNamara S; Shell RD; Orenstein DM; Rosenbluth D; Katz MF; Ahrens R; Hornick D; Joseph PM; Gibson RL; Aitken ML; Benton WW; Burns JL
Pediatr Pulmonol; 2011 Feb; 46(2):184-92. PubMed ID: 20963843
[TBL] [Abstract][Full Text] [Related]
20. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2012 Nov; 11():CD009528. PubMed ID: 23152277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
